BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22144423)

  • 1. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.
    Li H; Bitler BG; Vathipadiekal V; Maradeo ME; Slifker M; Creasy CL; Tummino PJ; Cairns P; Birrer MJ; Zhang R
    Cancer Prev Res (Phila); 2012 Mar; 5(3):484-91. PubMed ID: 22144423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
    Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
    Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
    Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
    Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
    Semaan A; Qazi AM; Seward S; Chamala S; Bryant CS; Kumar S; Morris R; Steffes CP; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
    Pharm Res; 2011 Dec; 28(12):3079-90. PubMed ID: 21818714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.
    Sarma K; Margueron R; Ivanov A; Pirrotta V; Reinberg D
    Mol Cell Biol; 2008 Apr; 28(8):2718-31. PubMed ID: 18285464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
    Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
    Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
    Fujii S; Ochiai A
    Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
    Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
    Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.